Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04259632 · ClinicalTrials.gov registry record · NA
Prolonged Daily Fasting as a Viable Alternative to Caloric Restriction in At-Risk Obese Humans
A NA study, sponsored by University of Minnesota.
- Completed
- Registry status
- NA
- Development phase
- 115
- Enrollment target
NCT04259632: Completed NA study, sponsored by University of Minnesota.
NCT04259632 is a NA study that has completed, run by University of Minnesota. The registered enrollment target is 115 participants, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (92% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT04259632, a NA study, has completed, sponsored by University of Minnesota.
- COMPLETED
- Registry status
- NA
- Development phase
- 115 participants
- Enrollment target
Study Summary
Purpose: Obesity is reaching epidemic proportions, affecting 36% of the adult population in the United States. There is intense interest in dietary management to treat obesity and its associated complications. The first line of obesity treatment is caloric restriction (CR), although recidivism is common. For moderate CR, attrition rates of 20% are often reported, therefore weight loss options beyond CR are urgently needed.
Primary Outcome
Weight will be measured by standard scale and reported in kilograms. This between 2 time points - baseline and 12 weeks
Interventions
- BEHAVIORAL Time Restricted Eating (TRE)
- BEHAVIORAL Caloric Restriction (CR)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 115 participants |
| Start Date | 2020-10-15 |
| Est. Completion | 2025-12-31 |
| Phase | NA |
What the finished NCT04259632 record still lists
NCT04259632 is an interventional study that assigns participants to a tested intervention. The registered 115 participants enrollment target is mid-sized for trials with a published cap, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (92% lower).
The record links to 0 conditions, and to 2 interventions - of which Time Restricted Eating (TRE) is the first listed.
NCT04259632 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT04259632 about?
NCT04259632 is a clinical study titled "Prolonged Daily Fasting as a Viable Alternative to Caloric Restriction in At-Risk Obese Humans". Purpose: Obesity is reaching epidemic proportions, affecting 36% of the adult population in the United States. There is intense interest in dietary management to treat obesity and its associated complications. The first line of obesity treatment is caloric restriction (CR), although recidivism is co...
What is the current status of trial NCT04259632?
This trial is currently completed. It is a NA study. The enrollment target is 115 participants. The study started on 2020-10-15. Estimated completion is 2025-12-31.
What interventions are being tested in trial NCT04259632?
The interventions under investigation include: Time Restricted Eating (TRE) (BEHAVIORAL), Caloric Restriction (CR) (BEHAVIORAL).
Who is sponsoring clinical trial NCT04259632?
This trial is sponsored by University of Minnesota, which has 966 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT04259632's enrollment target sits among peer trials
115 810th of 2000 higher than 1,190 of 2,000 other NA trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other NA trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02346929 · 115 participants · NA
Hematoma Block for Distal Radius Fracture
- NCT03394365 · 115 participants · Phase 3
A Phase 3 Study of Tabelecleucel for Participants With Epstein-Barr Virus-Associated Post-Transplant Lymphoproliferative Disease After Failure With Rituximab or Rituximab and Chemotherapy
- NCT03907475 · 115 participants · Phase 2
Durvalumab in Combination With Chemotherapy in Treating Patients With Advanced Solid Tumors, DURVA+ Trial
- NCT05086692 · 115 participants · Phase 1
A Beta-only IL-2 ImmunoTherapY Study
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI